← All trials
NCT05202379
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 11, 2022
- Primary completion
- Sep 30, 2022
- Completion date
- Sep 30, 2022
- First posted
- Jan 21, 2022
- Last posted
- Mar 10, 2022
- Enrollment
- 56
- Arms / groups
- 7 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Cocrystal Pharma, Inc.Lead sponsor
- Linear Clinical ResearchCollaborator
- Linear Clinical ResearchOverall official - principal investigator
- Cocrystal Pharma Australia Pty Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.